87 related articles for article (PubMed ID: 17908980)
1. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Overmoyer B; Fu P; Hoppel C; Radivoyevitch T; Shenk R; Persons M; Silverman P; Robertson K; Ziats NP; Wasman JK; Abdul-Karim FW; Jesberger JA; Duerk J; Hartman P; Hanks S; Lewin J; Dowlati A; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2007 Oct; 13(19):5862-8. PubMed ID: 17908980
[TBL] [Abstract][Full Text] [Related]
2. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
[TBL] [Abstract][Full Text] [Related]
3. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
[TBL] [Abstract][Full Text] [Related]
4. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
8. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
9. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
[TBL] [Abstract][Full Text] [Related]
10. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
Miller KD; Soule SE; Calley C; Emerson RE; Hutchins GD; Kopecky K; Badve S; Storniolo A; Goulet R; Sledge GW
Breast Cancer Res Treat; 2005 Jan; 89(2):187-97. PubMed ID: 15692762
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
18. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
[TBL] [Abstract][Full Text] [Related]
20. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
